A gene-edited pig liver transplanted into a human recipient remains functional after 10 days and indicates that porcine organs could help meet the growing demand for liver transplants.
Category: biotech/medical – Page 22
The research, published in [Proceedings of the National Academy of Sciences](https://www.pnas.org/cgi/doi/10.1073/pnas.2416106122), highlights the new drug’s potential as a treatment option for conditions like schizophrenia, where psychedelics are not prescribed for safety reasons. The compound also may be useful for treating other neuropsychiatric and neurodegenerative diseases characterized by synaptic loss and brain atrophy.
To design the drug, dubbed JRT, researchers flipped the position of just two atoms in LSD’s molecular structure. The chemical flip reduced JRT’s hallucinogenic potential while maintaining its neurotherapeutic properties, including its ability to spur neuronal growth and repair damaged neuronal connections that are often observed in the brains of those with neuropsychiatric and neurodegenerative diseases.
Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and schizophrenia (SCZ). Psychedelics possess a remarkable ability to promote cortical neuron growth and increase spine density; however, these compounds are contraindicated for patients with SCZ or a family history of psychosis. Here, we report the molecular design and de novo total synthesis of (+)-JRT, a structural analogue of lysergic acid diethylamide (LSD) with lower hallucinogenic potential and potent neuroplasticity-promoting properties. In addition to promoting spinogenesis in the cortex, (+)-JRT produces therapeutic effects in behavioral assays relevant to depression and cognition without exacerbating behavioral and gene expression signatures relevant to psychosis.
Cases of patients who recovered from trauma after dreaming under surgical anesthesia spur Stanford Medicine researchers to investigate dreaming as therapy.
A new study by Brown University researchers suggests that gold nanoparticles—microscopic bits of gold thousands of times thinner than a human hair—might one day be used to help restore vision in people with macular degeneration and other retinal disorders.
In a study published in the journal ACS Nano, the research team showed that nanoparticles injected into the retina can successfully stimulate the visual system and restore vision in mice with retinal disorders. The findings suggest that a new type of visual prosthesis system in which nanoparticles, used in combination with a small laser device worn in a pair of glasses or goggles, might one day help people with retinal disorders to see again.
“This is a new type of retinal prosthesis that has the potential to restore vision lost to retinal degeneration without requiring any kind of complicated surgery or genetic modification,” said Jiarui Nie, a postdoctoral researcher at the National Institutes of Health who led the research while completing her Ph.D. at Brown. “We believe this technique could potentially transform treatment paradigms for retinal degenerative conditions.”
Listening to favorite music activates the brain’s opioid system, which is involved in feelings of pleasure and pain relief, according to a new PET imaging study.
A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández University of Elche (UMH, Spain) has developed a new method to deliver cell therapies in patients on extracorporeal membrane oxygenation (ECMO), a life support system used in cases of severe lung failure.
The advance has been published in Stem Cell Research & Therapy. The team has opted not to patent the technique in order to encourage its use in public health systems once further clinical testing is completed.
The method—named CIBA, for “Consecutive Intrabronchial Administration”—enables the delivery of stem-cell-based treatments directly into the alveoli of critically ill patients who cannot receive standard intravenous cell therapy due to the ECMO system’s constraints.
This Review summarizes recent and compelling examples of microbiome-based interventions that are ripe for clinical adoption while also discussing the challenges and opportunities facing the field.
American composer Alvin Lucier was well-known for his experimental works that tested the boundaries of music and art. A longtime professor at Wesleyan University (before retiring in 2011), Alvin passed away in 2021 at the age of 90. However, that wasn’t the end of his lifelong musical odyssey.
Earlier this month, at the Art Gallery of Western Australia, a new art installation titled Revivification used Lucier’s “brain matter”—hooked up to an electrode mesh connected to twenty large brass plates—to create electrical signals that triggered a mallet to strike the varying plates, creating a kind of post-mortem musical piece. Conceptualized in collaboration with Lucier himself before his death, the artists solicited the help of researchers from Harvard Medical School, who grew a mini-brain from Lucier’s white blood cells. The team created stem cells from these white blood cells, and due to their pluripotency, the cells developed into cerebral organoids somewhat similar to developing human brains.
A light-activated enzyme morphed round starfish egg cells into different shapes. This technology could one day be useful for wound healing therapies.
Physicists at Harvard have developed a powerful new laser-on-a-chip that emits bright pulses in the mid-infrared spectrum – an elusive and highly useful light range for detecting gases and enabling new spectroscopic tools.
The device, which packs capabilities of much larger systems into a tiny chip, doesn’t need any external components. It merges breakthrough photonic design with quantum cascade laser tech and could soon revolutionize environmental monitoring and medical diagnostics by detecting thousands of light frequencies in one go.
Breakthrough in compact mid-infrared laser technology.